Baker McKenzie has suggested the shareholders of Swiss Cardio Applied sciences AG (“Swiss Cardio Applied sciences”), a medical firm specializing in cardiovascular surgical procedure options, on the sale of all their shares to Abacus Medication Group. Based in Denmark in 2004, Abacus Medication Group is a number one pharmaceutical firm targeted on the parallel import of medicines to boost entry and affordability.
Swiss Cardio Applied sciences AG, established by famend cardiovascular surgeons from the College of Berne, developed Cardioplexol®, an progressive cardioplegia resolution used to securely arrest the guts throughout advanced surgical procedures reminiscent of bypass operations and aortic repairs. The transaction is predicted to speed up worldwide commercialization and growth of Cardioplexol®, leveraging Abacus’ in depth international community alongside Swiss Cardio Applied sciences’ relationships in cardiothoracic surgical procedure.
Baker McKenzie suggested the shareholders of Swiss Cardio Applied sciences on all authorized facets of the transaction.
Zurich-based companions Alexander Fischer (M&A) and Julia Schieber (M&A, Healthcare & Sciences) led the staff, which consisted of the next: Matthias Trautmann (accomplice, M&A), Hesam Mirzai (affiliate, M&A) in addition to trainee legal professionals Elena Mani and Grégory Sarbach.
About Swiss Cardio Applied sciences AG
Swiss Cardio Applied sciences was based by a gaggle of cardiovascular surgical procedure specialists in 2008. Following greater than a decade of growth, scientific trials and regulatory approval, the corporate started industrial actions in Switzerland in 2023, with ambitions to develop additional into Europe and globally.
For extra data, go to: www.swisscardiotech.com
About Abacus Medication Group
The Abacus Medication Group contributes to international healthcare by offering higher entry to medicines. With a workforce of greater than 1,500 staff, the group generated income of EUR 1,487 million from gross sales throughout 35 nations in 2024. Acknowledged for its constant worthwhile development, Abacus continues to put money into individuals to stay an employer of alternative, whereas additionally advancing scalable digital excellence.
For extra data, go to: www.abacusmedicinegroup.com and www.abacusmedicinepharmaservices.com
